DHR Stock Overview

Designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More details

DHR fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 12.42% per year

Analysts in good agreement that stock price will rise by 20.9%

Risk Analysis

Significant insider selling over the past 3 months

My Notes

Capture your thoughts, links and company narrative

Danaher Corporation Competitors

Thermo Fisher Scientific

NYSE:TMO

US$228.6b

Agilent Technologies

NYSE:A

US$43.2b

Lonza Group

SWX:LONN

CHF 42.0b

IQVIA Holdings

NYSE:IQV

US$36.5b

Price History & Performance

Summary of share price highs, lows and changes for Danaher
Historical stock prices
Current Share Price	US$250.50
52 Week High	US$250.50
52 Week Low	US$250.50
Beta	0.86
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	DHR	PE Life Sciences	PE Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how DHR performed against the PE Life Sciences industry.

Return vs Market: Insufficient data to determine how DHR performed against the PE Market.

Price Volatility

Is DHR's price volatile compared to industry and market?
DHR volatility
DHR Average Weekly Movement	0%
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in PE Market	0%
10% least volatile stocks in PE Market	0%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine DHR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1969	63,000	Rainer Blair	www.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.

Danaher Corporation Fundamentals Summary

How do Danaher's earnings and revenue compare to its market cap?
DHR fundamental statistics
Market cap	US$160.17b
Earnings (TTM)	US$3.90b
Revenue (TTM)	US$23.88b

41.1x

P/E Ratio

6.7x

P/S Ratio

Is DHR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DHR income statement (TTM)
Revenue	US$23.88b
Cost of Revenue	US$9.67b
Gross Profit	US$14.21b
Other Expenses	US$10.31b
Earnings	US$3.90b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	5.42
Gross Margin	59.50%
Net Profit Margin	16.33%
Debt/Equity Ratio	32.3%

How did DHR perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

20%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/03 04:52
End of Day Share Price	2025/01/31 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Danaher Corporation is covered by 53 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Eade	Argus Research Company
Catherine Ramsey Schulte	Baird
Robert Cornell	Barclays